# A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Source: https://onco.cc/trials/nct07093814/  
OnCo record `nct07093814` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VRT106 in glioma & glioblastoma, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma is a phase 1/2 interventional study registered as NCT07093814 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 42 participants planned, started 2025-09-02 and due to reach its primary completion in 2028-12-31. Interventions recorded: VRT106.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07093814
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
- Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07093814: https://clinicaltrials.gov/study/NCT07093814

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07093814.json